Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Individualised drug therapy based on pharmacogenomics: focus on carboxylesterase 1 (CES1) Individuelle forskelle i omsætningen af lægemidler

Next Previous
Trial Profile

Individualised drug therapy based on pharmacogenomics: focus on carboxylesterase 1 (CES1) Individuelle forskelle i omsætningen af lægemidler

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 23 Sep 2013

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Methylphenidate (Primary) ; Trandolapril (Primary) ; Enalapril
  • Indications Atherosclerosis; Attention-deficit hyperactivity disorder; Heart failure; Hypertension; Myocardial infarction
  • Focus Pharmacogenomic; Pharmacokinetics
  • Acronyms INDICES-WP2

Most Recent Events

  • 21 Sep 2013 Planned number of patients changed from 35 to 45 as reported by European Clinical Trials Database record.
  • 08 Dec 2012 Additional drug 'enalapril' added as treatment arm as reported by European Clinical Trials Database record.
  • 27 Feb 2012 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top